Multidrug-resistant (MDR) tuberculosis disease is a major health threat globally. Nearly half a million MDR TB cases are estimated to occur worldwide annually, including cases that are extensively drug-resistant (XDR).

While MDR and XDR TB are relatively rare (fewer than 100 cases per year) in the United States, their treatment comes at a terrible price — it is very expensive, takes a long time to complete, disrupts lives, and has potentially life-threatening side effects. However, the number of drug-resistant cases in the United States remains stable due to effective control strategies.

### THE OUTSIZED FINANCIAL TOLL OF MDR AND XDR TB DISEASE

**COST INCREASES WITH GREATER RESISTANCE**

<table>
<thead>
<tr>
<th>TB Treatment: 6–9 months</th>
<th>$67,000</th>
<th>$20,000</th>
<th>Direct treatment costs: Drugs, diagnostics, case management, social work, housing, transportation, and hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDR TB Treatment: 20–26 months</td>
<td>$420,000</td>
<td>$182,000</td>
<td></td>
</tr>
<tr>
<td>XDR TB Treatment: 32 months</td>
<td>$801,000</td>
<td>$568,000</td>
<td></td>
</tr>
</tbody>
</table>

**Productivity loss during treatment, including deaths**

| $47,000 | $238,000 |

### SERIOUS SIDE EFFECTS experienced by many patients treated for drug-resistant TB:

- **19%** Depression/Psychosis
- **13%** Hearing Impairment
- **13%** Hepatitis
- **11%** Kidney Impairment
- **8%** Loss of Mobility
- **7%** Vision Impairment
- **1%** Seizures

### A MAJOR HUMAN COST of those treated for drug-resistant TB:

- **73%** Hospitalization
- **37%** Require Home Isolation
- **27%** Stop Working
- **9%** Die During Treatment

### MDR AND XDR TB IS PREVENTABLE AND CONTROLLABLE IN THE U.S. THROUGH:

- Better treatment options
- Rapid diagnosis
- Expert treatment of every TB case
- Improving global TB diagnosis and treatment

---

1. Multidrug-resistant TB is resistant to at least two of the best and most important anti-TB drugs (isoniazid and rifampin).
2. Extensively drug-resistant TB is resistant to isoniazid and rifampin among first-line drugs, resistant to any fluoroquinolone and at least one second-line injectable drug.


---

For more information visit [www.cdc.gov/nchhstp/newsroom](http://www.cdc.gov/nchhstp/newsroom)